Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
June 01, 2023 15:40 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 1, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
May 31, 2023 08:15 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
May 25, 2023 17:10 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphomaPoster presentations...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
May 23, 2023 15:14 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 23, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,098 shares as a consequence of the exercise of employee warrants. The...
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023 12:33 ET
|
Genmab A/S
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median...
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 11:01 ET
|
Genmab A/S
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In...
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
April 24, 2023 04:39 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second...
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
April 20, 2023 19:45 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc....
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
April 18, 2023 06:25 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023 02:00 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody...